Who are OZOGAMICIN's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Mylotarg, Mylotarg, GEMTUZUMAB OZOGAMICIN.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ozogamicin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

OZOGAMICIN — Competitive Intelligence Brief

OZOGAMICIN (OZOGAMICIN) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD33-directed Immunoconjugate [EPC].

marketed CD33-directed Immunoconjugate [EPC] Live · refreshed every 30 min

Target snapshot

OZOGAMICIN (OZOGAMICIN).

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
OZOGAMICIN TARGET	OZOGAMICIN		marketed	CD33-directed Immunoconjugate [EPC]
Mylotarg	GEMTUZUMAB	Wyeth Pharms Inc	marketed	CD33-directed Immunoconjugate [EPC]	Myeloid cell surface antigen CD33	2020-01-01
Mylotarg	gemtuzumab-ozogamicin	Pfizer	marketed	CD33-directed Immunoconjugate [EPC]	Myeloid cell surface antigen CD33	2000-01-01
GEMTUZUMAB OZOGAMICIN	GEMTUZUMAB OZOGAMICIN		marketed	CD33-directed Immunoconjugate [EPC]		2000-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD33-directed Immunoconjugate [EPC] class)

· 2 drugs in this class
Pfizer · 1 drug in this class
Wyeth Pharms Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). OZOGAMICIN — Competitive Intelligence Brief. https://druglandscape.com/ci/ozogamicin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab